• 1.

    Punukollu G, Gowda R, Khan I, 2007. Clinical aspects of the Chagas' heart disease. Int J Cardiol 115: 279283.

  • 2.

    Bern C, Kjos S, Yabsley MJ, Montgomery SP, 2011. Trypanosoma cruzi and Chagas' disease in the United States. Clin Microbiol Rev 24: 655681.

  • 3.

    Rassi A Jr, Rassi A, Rassi S, 2007. Predictors of mortality in chronic chagas disease: a systematic review of observational studies. Circulation 115: 11011108.

    • Search Google Scholar
    • Export Citation
  • 4.

    Klein N, Hurwitz I, Durvasula R, 2012. Globalization of Chagas disease: a growing concern in nonendemic countries. Epidemiol Res Int 2012: 113.

    • Search Google Scholar
    • Export Citation
  • 5.

    Prata A, 2001. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1: 9299.

  • 6.

    Higuchi M, Benvenuti L, Reis M, 2003. Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovasc Res 60: 96107.

    • Search Google Scholar
    • Export Citation
  • 7.

    Rassi A, Rassi A, Marin-Neto JA, 2010. Chagas disease. Lancet 375: 13881402.

  • 8.

    Ribeiro AL, Rocha MO, 1998. Indeterminate form of Chagas disease: considerations about diagnosis and prognosis. Rev Soc Bras Med Trop 31: 301.

    • Search Google Scholar
    • Export Citation
  • 9.

    Biolo A, Ribeiro A, Clausell N, 2010. Chagas cardiomyopathy—where do we stand after a hundred years? Prog Cardiovasc Dis 52: 300316.

  • 10.

    Viotti RJ, Vigliano C, Laucella S, Lococo B, Petti M, Bertocchi G, Ruiz Vera B, Armenti H, 2004. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart 90: 655660.

    • Search Google Scholar
    • Export Citation
  • 11.

    Chatterjee K, Zhang J, Honbo N, Karliner J, 2010. Doxorubicin cardiomyopathy. Cardiology 115: 155162.

  • 12.

    Piano MR, 2002. Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. Chest 121: 16381650.

  • 13.

    Viotti R, Vigliano C, Lococo B, 2006. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. Ann Intern Med 144: 724734.

    • Search Google Scholar
    • Export Citation
 
 
 

 

 
 
 

 

 

 

 

 

 

Rapidly Progressing Chagas Cardiomyopathy

View More View Less
  • Department of Cardiology, Olive View–University of California, Los Angeles (UCLA) Medical Center, Sylmar, California

Chagas disease, caused by the parasite Trypanosoma cruzi, can cause a potentially life-threatening cardiomyopathy in approximately 10–40% of afflicted individuals. The decline in cardiac function characteristically progresses over the course of many years. We report a case of Chagas disease in which the patient experienced an atypical rapid deterioration to severe cardiomyopathy over the course of 16 months. This case argues the need for increased routine surveillance for patients with confirmed T. cruzi infection, who are determined to be at high-risk for worsening cardiomyopathy.

Author Notes

* Address correspondence to John Hollowed, Olive View Medical Center, Department of Medicine, 14445 Olive View Drive, Sylmar, CA 91342. E-mail: jhollowed@dhs.lacounty.gov

Authors' addresses: John Hollowed, Department of Medicine, Olive View Medical Center, Sylmar, CA, E-mail: jhollowed@dhs.lacounty.gov. Matthew McCullough, Department of Medicine, Olive View–UCLA Medical Center, Sylmar, CA, E-mail: mmccullough3@dhs.lacounty.gov. Daniel Sanchez, Mahmoud Traina, and Salvador Hernandez, Department of Cardiology, Olive View–UCLA Medical Center, Sylmar, CA, E-mails: dsanchez@dhs.lacounty.gov, mtraina@dhs.lacounty.gov, and shernandez@dhs.lacounty.gov. Efrain Murillo, Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, E-mail: efrainaguilarmurillo@gmail.com.

Save